262 related articles for article (PubMed ID: 22366949)
21. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
Mansour MR; Abraham BJ; Anders L; Berezovskaya A; Gutierrez A; Durbin AD; Etchin J; Lawton L; Sallan SE; Silverman LB; Loh ML; Hunger SP; Sanda T; Young RA; Look AT
Science; 2014 Dec; 346(6215):1373-7. PubMed ID: 25394790
[TBL] [Abstract][Full Text] [Related]
22. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
[TBL] [Abstract][Full Text] [Related]
23. E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.
Pi WC; Wang J; Shimada M; Lin JW; Geng H; Lee YL; Lu R; Li D; Wang GG; Roeder RG; Chen WY
Blood; 2020 Jul; 136(1):11-23. PubMed ID: 32276273
[TBL] [Abstract][Full Text] [Related]
24. Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.
Noronha EP; Andrade FG; Zampier C; de Andrade CF; Terra-Granado E; Pombo-de-Oliveira MS;
Blood Cells Mol Dis; 2016 Mar; 57():74-80. PubMed ID: 26852660
[TBL] [Abstract][Full Text] [Related]
25. Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphoma.
Rakowski LA; Lehotzky EA; Chiang MY
PLoS One; 2011 Feb; 6(2):e16761. PubMed ID: 21326611
[TBL] [Abstract][Full Text] [Related]
26. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
27. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Kleppe M; Soulier J; Asnafi V; Mentens N; Hornakova T; Knoops L; Constantinescu S; Sigaux F; Meijerink JP; Vandenberghe P; Tartaglia M; Foa R; Macintyre E; Haferlach T; Cools J
Blood; 2011 Jun; 117(26):7090-8. PubMed ID: 21551237
[TBL] [Abstract][Full Text] [Related]
28. Elevated enhancer-oncogene contacts and higher oncogene expression levels by recurrent CTCF inactivating mutations in acute T cell leukemia.
Smits WK; Vermeulen C; Hagelaar R; Kimura S; Vroegindeweij EM; Buijs-Gladdines JGCAM; van de Geer E; Verstegen MJAM; Splinter E; van Reijmersdal SV; Buijs A; Galjart N; van Eyndhoven W; van Min M; Kuiper R; Kemmeren P; Mullighan CG; de Laat W; Meijerink JPP
Cell Rep; 2023 Apr; 42(4):112373. PubMed ID: 37060567
[TBL] [Abstract][Full Text] [Related]
29. TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.
Sanda T; Leong WZ
Exp Hematol; 2017 Sep; 53():7-15. PubMed ID: 28652130
[TBL] [Abstract][Full Text] [Related]
30. MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia.
Bardelli V; Arniani S; Pierini V; Pierini T; Di Giacomo D; Gorello P; Moretti M; Pellanera F; Elia L; Vitale A; Storlazzi CT; Tolomeo D; Mastrodicasa E; Caniglia M; Chiaretti S; Ruggeri L; Roti G; Schwab C; Harrison CJ; Almeida A; Pieters T; Van Vlierberghe P; Mecucci C; La Starza R
Genes Chromosomes Cancer; 2021 Jul; 60(7):482-488. PubMed ID: 33611795
[TBL] [Abstract][Full Text] [Related]
31. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.
Verboom K; Van Loocke W; Volders PJ; Decaesteker B; Cobos FA; Bornschein S; de Bock CE; Atak ZK; Clappier E; Aerts S; Cools J; Soulier J; Taghon T; Van Vlierberghe P; Vandesompele J; Speleman F; Durinck K
Haematologica; 2018 Dec; 103(12):e585-e589. PubMed ID: 29954933
[No Abstract] [Full Text] [Related]
33. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.
Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; Macleod RA
Leuk Lymphoma; 2011 Feb; 52(2):290-7. PubMed ID: 21261500
[TBL] [Abstract][Full Text] [Related]
35. Tlx3 and Runx1 act in combination to coordinate the development of a cohort of nociceptors, thermoceptors, and pruriceptors.
Lopes C; Liu Z; Xu Y; Ma Q
J Neurosci; 2012 Jul; 32(28):9706-15. PubMed ID: 22787056
[TBL] [Abstract][Full Text] [Related]
36. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.
Grossmann V; Kern W; Harbich S; Alpermann T; Jeromin S; Schnittger S; Haferlach C; Haferlach T; Kohlmann A
Haematologica; 2011 Dec; 96(12):1874-7. PubMed ID: 21828118
[TBL] [Abstract][Full Text] [Related]
37. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.
Grossmann V; Haferlach C; Weissmann S; Roller A; Schindela S; Poetzinger F; Stadler K; Bellos F; Kern W; Haferlach T; Schnittger S; Kohlmann A
Genes Chromosomes Cancer; 2013 Apr; 52(4):410-22. PubMed ID: 23341344
[TBL] [Abstract][Full Text] [Related]
38. TLX1/HOX11 transcription factor inhibits differentiation and promotes a non-haemopoietic phenotype in murine bone marrow cells.
Dixon DN; Izon DJ; Dagger S; Callow MJ; Taplin RH; Kees UR; Greene WK
Br J Haematol; 2007 Jul; 138(1):54-67. PubMed ID: 17555447
[TBL] [Abstract][Full Text] [Related]
39. Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
Tijchon E; van Emst L; Yuniati L; van Ingen Schenau D; Gerritsen M; van der Meer LT; Williams O; Hoogerbrugge PM; Scheijen B; van Leeuwen FN
Exp Hematol; 2018 Apr; 60():57-62.e3. PubMed ID: 29408281
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs.
Bergeron J; Clappier E; Radford I; Buzyn A; Millien C; Soler G; Ballerini P; Thomas X; Soulier J; Dombret H; Macintyre EA; Asnafi V
Blood; 2007 Oct; 110(7):2324-30. PubMed ID: 17609427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
